ValuEngine cut shares of Nektar Therapeutics (NASDAQ:NKTR) from a sell rating to a strong sell rating in a report released on Friday.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reiterated a hold rating and set a $54.00 target price on shares of Nektar Therapeutics in a report on Tuesday, July 31st. TheStreet upgraded Nektar Therapeutics from a d rating to a c rating in a report on Wednesday, August 8th. Mizuho reiterated a buy rating and set a $103.00 target price on shares of Nektar Therapeutics in a report on Thursday, August 9th. BidaskClub upgraded Nektar Therapeutics from a buy rating to a strong-buy rating in a report on Tuesday, August 14th. Finally, William Blair reiterated an outperform rating on shares of Nektar Therapeutics in a report on Thursday, August 9th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $85.78.

NKTR opened at $38.23 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.93 and a quick ratio of 13.80. Nektar Therapeutics has a 12 month low of $33.50 and a 12 month high of $111.36. The firm has a market capitalization of $6.62 billion, a P/E ratio of -69.51 and a beta of 2.91.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.07. Nektar Therapeutics had a net margin of 59.71% and a return on equity of 79.66%. The business had revenue of $27.80 million during the quarter, compared to analysts’ expectations of $26.08 million. During the same quarter in the prior year, the company earned $0.37 EPS. The firm’s quarterly revenue was down 81.8% on a year-over-year basis. As a group, sell-side analysts forecast that Nektar Therapeutics will post 3.66 earnings per share for the current fiscal year.

In other news, Director Jeffrey Robert Ajer sold 6,750 shares of the stock in a transaction dated Thursday, September 20th. The shares were sold at an average price of $56.76, for a total transaction of $383,130.00. Following the completion of the transaction, the director now directly owns 15,750 shares in the company, valued at approximately $893,970. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director R Scott Greer sold 10,000 shares of the stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $67.39, for a total transaction of $673,900.00. Following the transaction, the director now owns 140,333 shares of the company’s stock, valued at $9,457,040.87. The disclosure for this sale can be found here. In the last quarter, insiders have sold 46,750 shares of company stock valued at $2,855,830. Corporate insiders own 4.31% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Macquarie Group Ltd. lifted its position in Nektar Therapeutics by 966.0% during the second quarter. Macquarie Group Ltd. now owns 165,000 shares of the biopharmaceutical company’s stock worth $8,057,000 after acquiring an additional 149,522 shares during the last quarter. World Asset Management Inc lifted its position in Nektar Therapeutics by 16.6% during the second quarter. World Asset Management Inc now owns 10,646 shares of the biopharmaceutical company’s stock worth $520,000 after acquiring an additional 1,513 shares during the last quarter. Riverhead Capital Management LLC lifted its position in Nektar Therapeutics by 241.0% during the second quarter. Riverhead Capital Management LLC now owns 7,134 shares of the biopharmaceutical company’s stock worth $348,000 after acquiring an additional 5,042 shares during the last quarter. Gateway Investment Advisers LLC acquired a new stake in Nektar Therapeutics during the second quarter worth approximately $342,000. Finally, LMR Partners LLP acquired a new stake in Nektar Therapeutics during the second quarter worth approximately $6,378,000. Institutional investors own 91.42% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Read More: Bond

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.